TY - JOUR
T1 - A multi-institutional feasibility study on the use of automated screening systems for quality control rescreening of cervical cytology
AU - Sugiyama, Yuko
AU - Sasaki, Hiroshi
AU - Komatsu, Kyoko
AU - Yabushita, Ryuji
AU - Oda, Mizue
AU - Yanoh, Kenji
AU - Ueda, Masatsugu
AU - Itamochi, Hiroaki
AU - Okugawa, Kaoru
AU - Fujita, Hiromasa
AU - Tase, Toru
AU - Nakatani, Eiji
AU - Moriya, Takuya
N1 - Publisher Copyright:
© 2016 The Author(s) Published by S. Karger AG, Basel.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Objective: To evaluate the efficacy of the automated screening system FocalPoint for cervical cytology quality control (QC) rescreening. False-negative rates (FNRs) were evaluated by a multi-institutional retrospective study. Study Design: Cervical cytology slides that had already been reported as negative for intraepithelial lesion or malignancy (NILM) were chosen arbitrarily for FocalPoint rescreening. Slides stratified into the highest 15% probability of being abnormal were rescreened by a cytotechnologist. The slides that were abnormal were reevaluated by a cytopathologist to be false negatives. Results: Rescreening of 12,000 slides, i.e. 9,000 conventional slides and 3,000 liquid-based cytology (LBC) slides, was performed; 9,826 (7,393 conventional and 2,433 LBC) were satisfactory for FocalPoint (2,174 were determined unsatisfactory) and those within the highest 15% of probability (1,496, i.e. 1,123 conventional and 373 LBC) were rescreened. As a result, 117 (96 conventional and 21 LBC) were determined as abnormal (other than NILM) and the FNR was 1.19%. Among these 117 slides, 40 (35 conventional and 5 LBC) were determined as high-grade squamous intraepithelial lesion and greater (HSIL+). Conclusion: Of 117 (1.19%) abnormal slides detected, 40 (0.41%) were determined to be HSIL+. This result suggests that FocalPoint is effective for QC rescreening of cervical cytology.
AB - Objective: To evaluate the efficacy of the automated screening system FocalPoint for cervical cytology quality control (QC) rescreening. False-negative rates (FNRs) were evaluated by a multi-institutional retrospective study. Study Design: Cervical cytology slides that had already been reported as negative for intraepithelial lesion or malignancy (NILM) were chosen arbitrarily for FocalPoint rescreening. Slides stratified into the highest 15% probability of being abnormal were rescreened by a cytotechnologist. The slides that were abnormal were reevaluated by a cytopathologist to be false negatives. Results: Rescreening of 12,000 slides, i.e. 9,000 conventional slides and 3,000 liquid-based cytology (LBC) slides, was performed; 9,826 (7,393 conventional and 2,433 LBC) were satisfactory for FocalPoint (2,174 were determined unsatisfactory) and those within the highest 15% of probability (1,496, i.e. 1,123 conventional and 373 LBC) were rescreened. As a result, 117 (96 conventional and 21 LBC) were determined as abnormal (other than NILM) and the FNR was 1.19%. Among these 117 slides, 40 (35 conventional and 5 LBC) were determined as high-grade squamous intraepithelial lesion and greater (HSIL+). Conclusion: Of 117 (1.19%) abnormal slides detected, 40 (0.41%) were determined to be HSIL+. This result suggests that FocalPoint is effective for QC rescreening of cervical cytology.
UR - http://www.scopus.com/inward/record.url?scp=84989271341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84989271341&partnerID=8YFLogxK
U2 - 10.1159/000449499
DO - 10.1159/000449499
M3 - Article
C2 - 27673689
AN - SCOPUS:84989271341
SN - 0001-5547
VL - 60
SP - 451
EP - 457
JO - Acta Cytologica
JF - Acta Cytologica
IS - 5
ER -